Whether hemoglobin A 1c (HbA 1c Thus, the recommendation to use HbA 1c in place of glucose levels to screen for and diagnose diabetes has come under recent criticism, remains controversial, and is not universally accepted. 4, 5 The prediabetes state is denoted by impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or combined IFG and IGT. Recently, an HbA 1c value in the 5.7% to 6.4% range was added as a criterion for diagnosing prediabetes. 6 Persons in any one of these categories are considered to be at greater risk for the development of type 2 diabetes; patients with HbA 1c values in the narrower 6.0% to 6.4% range are considered at particularly high risk. 6 It is now well established that patients with prediabetes can derive long-term benefit from intensive lifestyle interventions and can delay progression to type 2 diabetes. Referral to an ongoing support program to provide these interventions is recommended 6 ; therefore, the identification of patients in a clinical setting who would qualify for such intervention is important.
A hemoglobin A 1c (HbA 1c ) level of 6.5% or more was recommended recently as a cutoff to diagnose diabetes mellitus when confirmed by repeated testing. 1 Recent analyses have demonstrated, however, that HbA 1c may not be suitable for diagnosing diabetes because of its low sensitivity in identifying persons with the disease. 2, 3 Thus, the recommendation to use HbA 1c in place of glucose levels to screen for and diagnose diabetes has come under recent criticism, remains controversial, and is not universally accepted. 4, 5 The prediabetes state is denoted by impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or combined IFG and IGT. Recently, an HbA 1c value in the 5.7% to 6.4% range was added as a criterion for diagnosing prediabetes. 6 Persons in any one of these categories are considered to be at greater risk for the development of type 2 diabetes; patients with HbA 1c values in the narrower 6.0% to 6.4% range are considered at particularly high risk. 6 It is now well established that patients with prediabetes can derive long-term benefit from intensive lifestyle interventions and can delay progression to type 2 diabetes. Referral to an ongoing support program to provide these interventions is recommended 6 ; therefore, the identification of patients in a clinical setting who would qualify for such intervention is important.
Although the use of HbA 1c testing as a laboratory method to diagnose diabetes has been extensively discussed and critiqued, it is unclear how well HbA 1c testing would identify patients with prediabetes. By using a clinic population with known prediabetes, we assessed the prevalence of patients who had HbA 1c levels in the range of 6.0% to 6.4% or in the broader range of 5.7% to 6.4%.
Research Design and Methods
In January 2007, we implemented a clinic-based type 2 diabetes prevention program known as Diet-ExerciseActivity-Lifestyle (DEAL). The DEAL program has been previously described. 7 Briefly, patients are referred after a provisional diagnosis of IFG is detected during a standard fasting blood chemistry panel. A stepped-care approach to prevention is used, with intensive lifestyle changes encouraged during the first 6 months and introduction of metformin treatment if there is any evidence of worsening glycemic control. The 2-hour oral glucose tolerance test (75 g 
Results
Data from the 242 patients were analyzed and reported as mean (SD). The mean age of the patients was 62 (SD, 11) years; 64.0% (155/242) were women, and 88.0% (213/242) were white. The mean fasting glucose level was 110 mg/dL (6.1 mmol/L; SD, 8 mg/dL [0.4 mmol/L]), the 2-hour glucose level was 137 mg/dL (7.6 mmol/L; SD, 35 mg/dL [1.9 mmol/L]), and HbA 1c was 5.8% (SD, 0.36%). IFG alone was detected in 136 (56.2%) of the 242 patients, and combined IFG and IGT was found in 90 (37.2%). Because of the small number of patients in the IGT-only group (n = 8), their data were included with those for the combined IFG and IGT group for further analysis.
Only 28.5% (69/242) of patients had HbA 1c values in the range of 6.0% to 6.4% ❚Table 1❚, with a significantly higher prevalence in women than in men (P = .02); no differences were found by age. Among patients with isolated IFG, 29.4% (40/136) had HbA 1c values in the 6.0% to 6.4% range, with a trend toward a higher prevalence among women than among men (P = .08) and no difference by age. Finally, the percentage of patients with HbA 1c values in the 6.0% to 6.4% range in the combined IFG and IGT group was also low overall (27.8% [25/90]), with no significant difference between sex or age groups.
We next examined the proportion of patients who had HbA 1c values within the broader 5.7% to 6.4% range. With the lower boundary, about two thirds or fewer of patients typically had HbA 1c values in this range. Compared with women, men overall (P = .03) and men with isolated IFG (P = .02) had a significantly lower percentage of HbA 1c levels in the 5.7% to 6.4% range.
Discussion and Conclusion
There is no test with 100% sensitivity that can identify persons at highest risk for diabetes 8 ; persons with glucose levels and HbA 1c values even in the normal range still face a risk of diabetes. Nevertheless, practitioners need some guidance about how to screen for patients who may have prediabetes so that referrals can be made for appropriate prevention strategies.
Epidemiological studies have recently suggested that using HbA 1c is not an optimal screening strategy for the diagnosis of diabetes. 2, 3 From a clinical chemistry standpoint, many factors can lead to individual variability in HbA 1c , making it a less than optimal test to assess glycemia. For example, ethnic variability in HbA 1c levels has been documented in persons with prediabetes. 9 In addition, "high glycators" and "low glycators," possibly owing to differences in erythrocyte 2,3-diphosphoglycerate levels, have been described. 10, 11 A recent study in a general Dutch population suggested that HbA 1c values correlated poorly with fasting and 2-hour glucose levels in patients with mild hyperglycemia. 3 Our analysis looked specifically at how HbA 1c testing might have identified patients if it had been used as the screening test to identify persons who would benefit from a diabetes prevention program. Our data suggest, at least in this clinic population, that HbA 1c may not be the optimal screening test to identify persons with prediabetes. Fewer than one third of the persons in our study had an HbA 1c value actually within the range currently defined as high risk for development of type 2 diabetes (ie, 6.0%-6.4%). Although decreasing the lower boundary of the range increased the number of persons with prediabetes who would have been identified, about one third of the patients would still have been missed. Moreover, the lower limit of the broader range (ie, 5.7%) overlaps with the upper limit of our normal HbA 1c assay range; advocating this as a cutoff to select candidates for diabetes prevention likely would cause confusion among practitioners.
There are several limitations to our analysis. The DEAL program is underrepresented by members of racial and ethnic groups who are at highest risk for type 2 diabetes. In addition, the population typically is older, and the sample of persons with isolated IGT was small. Moreover, all patients in this study were preselected on the basis of already having IFG. Sensitivities and specificities cannot be calculated, and generalizations to the general population cannot be made.
Nevertheless, our data suggest that reliance on HbA 1c alone as a screening tool to identify persons who would benefit from a diabetes prevention program would miss a substantial number of eligible patients. It therefore seems reasonable to continue using fasting glucose levels, at least for our diabetes prevention program, as the initial screening method for determining eligibility for participation. . The numbers of patients in the 2 HbA 1c groups do not equal the total number of patients by category because the 6.0%-6.4% group is a subset of the 5.7%-6.4% group. The numbers of patients in the IFG-only group (n = 136) and in the combined IFG and IGT group (n = 90) do not equal the total number of patients (N = 242) because of missing data.
